# Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience

> **NCT06857500** · — · COMPLETED · sponsor: **Federico II University** · enrollment: 200 (actual)

## Conditions studied

- Classic Hodgkin Lymphoma
- Advanced Hodgkin Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06857500
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-01
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857500, "Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06857500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*